Tumor-infiltrating lymphocytes show ‘dramatic’ results in metastatic melanoma

Source: Healio, April 2021

More than 80% of patients with heavily pretreated metastatic melanoma experienced tumor shrinkage after receiving the adoptive cell therapy lifileucel, according to results of a phase 2 study.

The study — presented during the virtual American Association for Cancer Research Annual Meeting — was the first to examine the efficacy of tumor-infiltrating lymphocytes (TILs) for unresectable or metastatic melanoma in the post-PD-1 inhibitor era, according to Jason A. Chesney, MD, PhD, director of James Graham Brown Cancer Center and associate vice president for health affairs at University of Louisville.

READ THE ORIGINAL FULL ARTICLE